Acadia Pharmaceuticals | ACAD - Current Assets

Stock Price
26.04
Daily Change
0.91 3.62%
Monthly
-0.42%
Yearly
40.68%
Q1 Forecast
24.36

Acadia Pharmaceuticals reported $1.08B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
ALKERMES USD 1.74B 106.38M Sep/2025
Alnylam Pharmaceuticals USD 3.95B 309.11M Sep/2025
Biogen USD 8.94B 968.9M Sep/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Corcept Therapeutics USD 541.13M 98.02M Sep/2025
Cytokinetics USD 977.35M 90.81M Sep/2025
Eisai JPY 790.7B 27.55B Sep/2025
Eli Lilly USD 62.07B 12.22B Sep/2025
Incyte USD 4.28B 634.19M Sep/2025
J&J USD 54.61B 113M Sep/2025
Moderna USD 6.6B 427M Sep/2025
Neurocrine Biosciences USD 2.16B 409.5M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Prothena USD 339.97M 45.51M Sep/2025
PTC Therapeutics USD 2.01B 265.07M Sep/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 10.57B 141.7M Sep/2025